
JANUARY
2020
"You are unique - and so is your treatment"
"You are unique - and so is your treatment"
NEWS
The FDA has granted an accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
Share on:
We would like to share with you a comment in regard to the corona virus pandemia. Due to the current events, more information should be highlighted relating to our field of medicine
1O - Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy
Contact us for a free consultation with our specialized oncology team.